Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 316-323

  Termeer, Christian C ^a   Schirrmacher, Volker ^b   Bröcker, Eva Bettina ^c   Becker, Jürgen C ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Costimulatory molecules; Immunotherapy; Tumor immunity; Vaccination

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; OKT 3;

ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOMA CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 0034037655     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700109     Document Type: Article

References (39)

1. Cassel WA, Garret RE. Newcastle disease virus as an antineoplastic agent. Cancer. 1965;18:863-868.
2. Hersey P. Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann N Y Acad Sci. 1993;690:167-177.
3. Dalgleish A. The case for therapeutic vaccines. Melanoma Res. 1996;1996:6:5-10.
4. Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev. 1993;17:619-627.
5. Wallack MK, Sivanandham M, Ditaranto K, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg. 1997; 226:196-206.
6. Cassel WA, Murray DR. Treatment of stage II malignant j melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul. 1988;7:351-352.
7. Cassel WA, Murray DR. A ten-year follow-up on stage II ' malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 1992;9:169-171.
8. Stoeck M, Marland-Noske C, Manasterski M, et al. In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells. Cancer Immunol Immunother. 1993;37:240-244.
9. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol. 1995;13:171-173.
10. Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2:21-28.
11. 2b. Int J Oncol. 1995;6:947-954.
12. Ahlert T, Schirrmacher V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res. 1990;50:5962-5968.
13. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficiency parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol. 1997;15:1354-1366.
14. Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52:448-453.
15. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity. J Natl Cancer Inst. 1988;80:1305-1312.
16. von Hoegen P, Weber E, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: augmentation of the tumor-specific T cell responses in the absence of an anti-viral response. Eur J Immunol. 1988;18: 1159-1166.
17. von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/β. Cell Immunol. 1990;126:80-90.
18. Schirrmacher V, Ahlert T, Probstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol. 1998;25: 677-679.
19. Schirrmacher V, Haas C, Bonifer R, Ertel C. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res. 1997;3:1135-1148.
20. Mathiot C, Robin E, Gey A, Wenig X, et al. Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. Eur J Cancer. 1992;28:345-350.
21. + T helper cell clones in human melanoma. Cell Immunol. 1994;156:170-179.
22. Schwartz RH. T-cell clonal anergy. Curr Opin Immunol. 1997;9:351-357.
23. Civil A, Verweij CL. Regulation of IL2 gene transcription via the T-cell accessory molecule CD28. Res Immunol. 1995;146:158-164.
24. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science. 1991;251:313-316.
25. Ghosh P, Tan TH, Rice NR, et al. The interleukin 2 CD28-responsive complex contains at least three members of the NF-κB family: c-Rel, p50, and p65. Proc Natl Acad Sci USA. 1993;90:1696-1700.
26. Civil A, Geerts M, Aarden LA, Verweij CL. Evidence for a role of CD28RE as a response element for distinct mitogenic T cell activation signals. Eur J Immunol. 1992; 22:3041-3046.
27. + T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol. 1995;7:891-904.
28. Augustin M, Dietrich A, Niedner R, et al. Phorbol-12-myristate-13-acetate-treated human keratinocytes express B7-like molecules that serve a costimulatory role in T-cell activation. J Invest Dermatol. 1993;100:275-281.
29. Denfeld RW, Dietrich A, Wuttig C, et al. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer. 1995;62:259-265.
30. Mersey P, Si Z, Smith MJ, Thomas WD. Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer. 1994;58:527-532.
31. + melanoma. Int Immunol. 1993;5:1501-1508.
32. Luscher UL, Filgueira L, Juretic A, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumorinfiltrating lymphocytes. Int J Cancer. 1994;57:612-619.
33. Grewal IS, Flavell RA. The role of CD40-ligand in costimulation and T-cell activation. Immunol Rev. 1996;153: 85-106.
34. Thomas WD, Smith MJ, Si Z, Hersey P. Expression of the costimulatory molecule CD40 on melanoma cells. Int J Cancer. 1996;68:795-801.
35. Becker JC, Termeer C, Schmidt RE, Brocker EB. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 1993;151: 7224-7232.
36. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with mini extracts prepared from a small number of cells. Nucleic Acids Res. 1989;20:4305-4310.
37. + T-cell responses. Curr Biol. 1994;4:499-505.
38. Umansky V, Shatrov VA, Lehmann V, Schirrmacher V. Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-κB. Int Immunol. 1996;8:491-498.
39. Plaksin D, Porgador A, Vadai E, et al. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer. 1994;59:796-801.